Cognitive Screening in Lung Cancer Patients
Recruiting · NCT06727370 · Observational (researchers observe without assigning treatment) · Lead sponsor: European Institute of Oncology
View the official record on ClinicalTrials.gov →What this trial is about
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
Exclusion criteria
- Age ≥ 70
- Presence of brain metastases
- Patients with concomitant neurological or psychiatric disorders.
- Patients undergoing brain radiotherapy
- Previous diagnosis of lung cancer
Where it is running
1 location listed.
- Istituto Europeo di Oncologia - Milan, Italy